Sickle Cell Disease: Pathophysiology, Symptoms & Treatment
This paper provides a thorough examination of sickle cell disease, a hereditary red blood cell disorder first described in Western medical literature in 1910. Beginning with the molecular and genetic foundations of the condition — including hemoglobin structure, the beta-globin mutation on chromosome 11, and the polymerization of sickle hemoglobin — the paper proceeds to detail the wide range of physical manifestations seen across the lifespan, from dactylitis and splenic sequestration in infants to vasoocclusive crises, stroke, and organ damage in adults. Treatment strategies are reviewed, including hydration, analgesics, infection prophylaxis, hydroxyurea therapy, and bone marrow transplantation. The paper concludes by emphasizing the absence of a cure and the need for comprehensive, multidisciplinary patient care.
- Introduction to Sickle Cell Disease: Historical discovery and early description of the disease
- Pathophysiological Basis of Sickle Cell Disease: Hemoglobin genetics, mutation mechanism, and sickling process
- Physical Manifestations of Sickle Cell Disease: Clinical symptoms across organ systems and life stages
- Treatment Options for Sickle Cell Disease: Crisis management, hydroxyurea therapy, and transplantation
- Conclusion: Chronic burden and need for comprehensive care
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper builds logically from molecular biology (hemoglobin structure and genetic mutation) to clinical presentation and then to treatment, giving readers a coherent explanatory framework before introducing symptoms.
- It uses concrete analogies — such as the water balloon and icicles comparison — to make abstract biochemical processes accessible without sacrificing accuracy.
- The discussion of treatment is well-grounded in clinical realities, including drug eligibility criteria for hydroxyurea and the limitations of bone marrow transplantation, demonstrating awareness of practical constraints.
Key academic technique demonstrated
The paper exemplifies a pathophysiology-first organizational strategy: by explaining the molecular defect (valine substitution at position 6 of the beta chain, chromosome 11 mutation, hemoglobin polymerization) before describing symptoms, the author ensures that every clinical manifestation — pain crises, stroke, autosplenectomy, retinal infarcts — is causally grounded rather than merely listed. This approach turns a catalog of symptoms into a coherent disease narrative.
Structure breakdown
The paper is divided into four substantive sections following a brief introduction: (1) pathophysiological basics covering hemoglobin biochemistry and genetics; (2) physical manifestations organized roughly by body system and age of onset; (3) treatment options from acute crisis management to long-term pharmacotherapy; and (4) a brief conclusion. References follow the body and include peer-reviewed journal articles from the 1990s, consistent with the paper's composition period.
Introduction to Sickle Cell Disease
Sickle cell disease — formerly called sickle cell anemia — is an inherited disease of the red blood cells. It was first reported in Western medical literature in 1910, when a Midwestern physician described a patient from the West Indies who had an anemia characterized by unusually shaped cells. In the 1920s, it was shown that the transformation of these cells into the characteristic sickle shape was associated with conditions of low oxygen. The abnormal hemoglobin associated with sickle cell disease was first demonstrated in 1948, when the process of protein electrophoresis showed that the hemoglobin in patients with sickle cells was different from that of the average patient.
References
Bailey, K.; Morris, J.S.; Thomas, P.; Serjeant, G.R. 1992. Fetal hemoglobin and early manifestations of homozygous sickle cell disease. Arch. Dis. Child. 67:517–20.
Charache, et al. 1995. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med. 332:1317–22.
Platt, O.S.; Brambilla, D.J.; Rosse, W.F.; Milner, P.F.; Castro, O.; Steinberg, M.H.; Klug, P.P. 1994. Mortality in sickle cell disease: life expectancy and risk factors for early death. N. Engl. J. Med. 330:1639–44.
Powars, D., et al. 1993. Sickle cell anemia: beta-S gene cluster haplotypes as genetic markers for severe disease expression. Am. J. Dis. Child. 147:1197–1202.
Powars, D., et al. 1994. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia: use in predicting clinical severity. Am. J. Ped. Hematology-Oncology 16:55–61.
Seltzer, W.K.; Abshire, T.C.; Lane, P.A.; Roloff, J.S.; Githens, J.H. 1992. Molecular genetic studies in Black families with sickle cell anemia and unusually high levels of fetal hemoglobin. Hemoglobin 16:363–77.
Walters, M.C.; Patience, M.; Leisenring, W.; Eckman, J.R.; Scott, J.P.; Mentzer, W.C.; Davies, S.C.; Ohene-Frempong, K.; Bernaudin, F.; Matthews, D.C.; Storb, R.; Sullivan, K.M. 1996. Bone marrow transplantation for sickle cell disease. N. Engl. J. Med. 335:369–376.
Create your account
Always verify citation format against your institution’s current style guide requirements.